Brook Byers, the health care venture capitalist at famed tech investor Kleiner Perkins Caulfield & Byers, has been investing in biotech companies for 38 years.
He invested in Genentech, the biotech stalwart, in the 1970s, and later on in Applied Biosystems, whose DNA sequencers were used to map the human genome in 2000.
Now Byers says there is a new “crescendo” in life sciences, as the cost to sequence human DNA drops dramatically. And he is putting his effort behind helping to build a new company, called Foundation Medicine, that is aiming to use gene-sequencing technology to help doctors pick the right drugs for cancer treatments with a test that is expected to cost several thousand dollars.
Full Story: Google, Tech Investor Back Company That Aims To Bring DNA Sequencing To Cancer Patients